 DBV Technologies the Company Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT, a clinical-stage biopharmaceutical company, today announced that given the Company has not yet received an update from the U.S. Food and Drug Administration FDA regarding its Biologics License Application BLA for ViaskinTM Peanut, it has undergone a comprehensive business review to best position DBV for the possibility of a delay in timelines for the Viaskin Peanut BLA review. As a result, the Board of Directors has approved the immediate initiation of a global and comprehensive restructuring plan, which is expected to include a significant reduction in workforce. 